TSC2
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (NCT05103358) | Aadi Bioscience, Inc. | 2022-02-15 |
| Everolimus for Cancer With TSC1 or TSC2 Mutation (NCT02201212) | Dana-Farber Cancer Institute | 2014-09-01 |
| Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation (NCT03817515) | Aadi Bioscience, Inc. |
Track TSC2 automatically
Every clearance here is in the API, with alerts when new ones post.